Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity. There is no discussion of any capital raising activities in the Q1 FY23 earnings call held on August 18, 2022. The management focuses on commercial expansion, product launches, and improving profitability without mentioning any new funding rounds. Capex and R&D investments are being managed internally without indication of external fundraising. Hence, based on available information, no new debt or equity fundraising is planned or announced as of this call.

Any current/future capex/capital investment/strategic investment?

No explicit mention of new or upcoming CAPEX or capital investments in the transcript. CFO Vamsi Krishna Potluri noted that depreciation remained nominal in FY23, as major capitalization happened in FY22, indicating limited new CAPEX in the current fiscal year. The company is focusing on commercializing new products (e.g., Sitagliptin, Ibuprofen) and expanding R&D (planned growth of 20% in R&D spend in FY23). Emphasis placed on strategic investments in product launches, geographic expansion, and customer addition rather than heavy capital expenditure. Inventory build-up was noted for launching

Future growth expectations in sales/revenue/volumes?

Ibuprofen is a flagship product with recent CEP approval, enabling sales in European markets and expected to generate good revenues going forward. Targeting 30-35% growth in Ibuprofen contribution. Plans to add 8 to 10 new products to the portfolio in the next year to increase non-ARV product revenue share. Sitagliptin launch is recent; Indian market estimated around 150+ tons, offering significant opportunity. The company is focused on expanding market share domestically and internationally, especially for newly launched products. ARV product Tenofovir contributes around 35% of revenue; sales

Future growth expectations in earnings/operating earnings/profits/EPS?

The company is optimistic about turning EBITDA positive by end of Q2 FY23 and PAT positive by end of FY23 (Page 12). Strong focus on commercializing Ibuprofen in Europe after CEP approval, targeting significant revenue growth (Pages 6, 13). Ibuprofen revenue contribution could grow to 35-40% of the top line by FY23-24 (Page 6). Growth expected from newly launched products such as Sitagliptin with an India market size assumption of around 150 tons and targeting good market share (Pages 14-15). ARV product Tenofovir sales remain uncertain due to tender dependencies; company working to diversify

Current/ Expected Orderbook/ Pending Orders?

The company is currently facing difficulty in predicting orderbook due to delays and uncertainty in government tenders, especially in the ARV segment. Clarity on ARV orders and tender outcomes is expected by the next quarter. Inventory buildup (approx. ₹275 crore) is partly due to readiness for product launches like Sitagliptin and Molnupiravir. The company is actively pushing partners for demand forecasts and contract manufacturing projections. Ibuprofen and other products are gaining traction, with aims to increase capacity utilization from 22% in Q1 to 70-80% by Q4 FY23. New product launche

SMS Pharma.Q1 FY23Pharmaceuticals & Biotechnology

SMS Pharma. Q1 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹485.8P/E: 44.4Market Cap: ₹4.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Ibuprofen is a flagship product with recent CEP approval, enabling sales in European markets and expected to generate good revenues going forward.
Targeting 30-35% growth in Ibuprofen contribution.
Plans to add 8 to 10 new products to the portfolio in the next year to increase non-ARV product revenue share.
Sitagliptin launch is recent; Indian market estimated around 150+ tons, offering significant opportunity.
The company is focused on expanding market share domestically and internationally, especially for newly launched products.
ARV product Tenofovir contributes around 35% of revenue; sales depend on tender outcomes with some growth potential.
Joint Venture (JV) products could contribute 20-25% of revenue, up from around 15%.
Overall, non-ARV products are positioned for significant growth to diversify revenue and reduce dependence on ARV APIs.
FY23 is expected to see improved capacity utilization and sales volumes, with EBITDA and PAT positive turnaround targeted.

Margin guidance

Category 3

The company is optimistic about turning EBITDA positive by end of Q2 FY23 and PAT positive by end of FY23 (Page 12).
Strong focus on commercializing Ibuprofen in Europe after CEP approval, targeting significant revenue growth (Pages 6, 13).
Ibuprofen revenue contribution could grow to 35-40% of the top line by FY23-24 (Page 6).
Growth expected from newly launched products such as Sitagliptin with an India market size assumption of around 150 tons and targeting good market share (Pages 14-15).
ARV product Tenofovir sales remain uncertain due to tender dependencies; company working to diversify product mix to reduce dependence on ARV (Pages 12, 15).
Launches from JV expected to contribute 20-25% of revenue, with focus on new products post-patent expiry (Page 8).
R&D expenses expected to increase by about 20% in FY23, supporting new product launches (Page 4).
Overall, the company is confident of overcoming short-term challenges and plans steady revenue and profitability growth through new product launches, customer additions, and geographical expansion (Pages 3-4).

See what SMS Pharma. management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or planned fundraising through debt or equity.
There is no discussion of any capital raising activities in the Q1 FY23 earnings call held on August 18, 2022.
The management focuses on commercial expansion, product launches, and improving profitability without mentioning any new funding rounds.
Capex and R&D investments are being managed internally without indication of external fundraising.
Hence, based on available information, no new debt or equity fundraising is planned or announced as of this call.

Order book

The company is currently facing difficulty in predicting orderbook due to delays and uncertainty in government tenders, especially in the ARV segment.
Clarity on ARV orders and tender outcomes is expected by the next quarter.
Inventory buildup (approx. ₹275 crore) is partly due to readiness for product launches like Sitagliptin and Molnupiravir.
The company is actively pushing partners for demand forecasts and contract manufacturing projections.
Ibuprofen and other products are gaining traction, with aims to increase capacity utilization from 22% in Q1 to 70-80% by Q4 FY23.
New product launches (including Sitagliptin in India) provide significant revenue potential and order flow opportunities.
The business is focused on diversifying revenue streams beyond ARV products and expanding into domestic and international markets.

See what SMS Pharma. management said on order book — free account, 30 seconds.

Capex plans

Yes

No explicit mention of new or upcoming CAPEX or capital investments in the transcript.
CFO Vamsi Krishna Potluri noted that depreciation remained nominal in FY23, as major capitalization happened in FY22, indicating limited new CAPEX in the current fiscal year.
The company is focusing on commercializing new products (e.g., Sitagliptin, Ibuprofen) and expanding R&D (planned growth of 20% in R&D spend in FY23).
Emphasis placed on strategic investments in product launches, geographic expansion, and customer addition rather than heavy capital expenditure.
Inventory build-up was noted for launching Sitagliptin and COVID-related drugs, but raw material purchases and major CAPEX are under control.
Overall, strategic focus is on operational expansion rather than announced large-scale capital investments at this time.

Track SMS Pharma. — get its next earnings analysis in your feed

How does SMS Pharma. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisSMS Pharma.

Rev 2Mar 3

See where SMS Pharma. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does SMS Pharma. rank in Pharmaceuticals & Biotechnology?

Compare SMS Pharma. against every Pharmaceuticals & Biotechnology company (Q1 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What SMS Pharma.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →